We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,104

Member States cannot impose uniform retail prices for prescription-only medicinal products, highest EU Court says
  • White & Case LLP
  • European Union, Germany
  • October 21 2016

EU law precludes national legislation setting fixed retail prices for prescription medicinal products, as it unreasonably restricts imports On 19


Royalties for revoked patents do not necessarily breach EU competition rules
  • Penningtons Manches LLP
  • European Union, Germany, USA
  • October 25 2016

It is hard to imagine that when Genentech signed a licence agreement in 1992 with Sanofi's predecessor, it could have foreseen the litigation storm


IP in the life sciences industries 2013
  • Intellectual Asset Management
  • Canada, Germany, India, Mexico, Sweden, USA
  • May 24 2013

No matter what stage of the business cycle they have reached, it is critical for companies in the life sciences sector to identify, protect and


Decision on stricter anti-corruption rules in healthcare sector deferred
  • CMS
  • Germany
  • October 28 2013

Tightening anti-corruption rules in the healthcare sector has been on the government's agenda for some time. The debate about the scope and


Amendments to German Drug Advertising Act
  • Baker McKenzie
  • Germany
  • March 26 2013

Amendments have been made to the German Drug Advertising Act (HeilmittelwerbegesetzHWG) (Act) by the so-called "Second Act Amending Drug Law and


Referral to the CJEU on third party supply under Bolar exemption
  • Taylor Wessing
  • European Union, Germany, Poland
  • December 10 2013

The Düsselorf Court of Appeal refers questions to the CJEU on third party supply for Bolar exemption purposes The Düsseldorf Court of


Rebates and bonuses by pharmacies to customers for Rx-drugs comprehensively outlawed
  • Baker McKenzie
  • Germany
  • August 19 2013

Bonuses, rebates, coupons and similar customer fidelity systems, which are offered by pharmacies to customers in exchange for the redemption of their


Johnson & JohnsonNovartis another challenge to pay for delay: is this ever permissible?
  • Bryan Cave LLP
  • European Union, France, Germany, Italy, United Kingdom
  • January 14 2014

In the latest challenge to so-called “pay for delay” or “reverse payment” agreements, on 10 December 2013, the European Commission fined the


Price fixing not justified to protect pharmacies in rural areas
  • Bryan Cave LLP
  • European Union, Germany
  • October 26 2016

On 19 October 2016, the Court of Justice of the European Union (CJEU) issued an important judgment concerning the German law on fixing prices of


Dispelling the Myriad gene patent harmonization myth
  • Foley & Lardner LLP
  • Australia, Canada, European Union, France, Germany, Japan, USA
  • April 30 2013

In the wake of the Supreme Court oral arguments in the Myriad "gene patent" case, most commentators are predicting that the Court will uphold the